A patient with ultra–high-risk multiple myeloma achieved deep and durable remission after ASCT combined with BCMA CAR-T therapy, maintaining sCR with MRD negativity for more than 18 months, highlighting a promising strategy for overcoming high-risk disease.
As CAR-T therapy reshapes treatment for multiple myeloma worldwide, China is emerging as a key alternative with strong research, lower costs, and faster access.
This real-world case highlights Eque-cel (Fucaso), a fully human BCMA-targeted CAR-T therapy, achieving deep and durable remission in a heavily pretreated multiple myeloma patient following two transplant relapses.
Eque-cel CAR-T Therapy Shows Durable Efficacy and Strong Safety Profile in Heavily Pretreated Multiple Myeloma Patients
Learn how BCMA CAR-T therapy works to treat multiple myeloma. This easy-to-understand guide explains benefits, side effects, and what patients can expect from this breakthrough immunotherapy.
Fucaso (Equecabtagene Autoleucel) is an innovative CAR-T cell therapy for multiple myeloma. Mrs. Thanyaphat from Thailand has been diagnosed with multiple myeloma, however, she ran out of option at home,
Multiple myeloma (MM) remains an incurable blood cancer with high relapse and drug resistance rates. Discover how emerging immunotherapies are reshaping treatment and offering new hope for patients.
Fucaso (Equecabtagene autoleucel) shows high efficacy in refractory/relapsed multiple myeloma, with a 96% overall response rate and 74.3% achieving complete response or better.
The world’s first fully-human BCMA CAR T-cell therapy, Fucaso, has been approved in China for r/r multiple myeloma.
CAR T-cell therapy is a personalized treatment. Feel free to contact us, find out whether CAR T-cell therapy is the right treatment for you or your loved one.
Whether you’re a patient, caregiver, or medical professional, our team can connect you with leading CAR-T treatment centers and clinical experts in China.
Fill out the form below and we’ll get back to you shortly with personalized support.